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1. Introduction
Osteoporosis is a systemic skeletal disease characterized by low bone mineral density
(BMD), microarchitectural deterioration of bone tissue, and an increase in fracture risk [1].
Several drugs have been developed to treat osteoporosis: most of these are inhibitors of bone
resorption. Effective treatment of osteoporosis requires not only resorption inhibitors, but al‐
so stimulators of bone formation especially in patients who already have lost a significant
degree of bone. Although therapeutic alternatives are available for inhibiting bone resorp‐
tion, options of bone anabolic agents are much more limited with regard to the bone resorp‐
tion inhibitors.
Although patients included in randomised controlled trials have osteoporosis defined ac‐
cording to the WHO criteria, i.e. a T score below -2.5 SD and/or prevalent fragility fractures,
a large proportion of fractures occurs at T-scores above -2.5 SD and in patients without prior
fractures [1]. Therefore, therapies with proven fracture risk reduction efficacy in patients
with osteopenia and/or clinical risk factors may contribute to earlier and more effective in‐
tervention against fractures.
The past decade has witnessed major advances in the diagnosis and treatment of osteoporo‐
sis. It would appear that anabolic drugs challenge prevailing paradigm by stimulating bone
formation, therefore enhancing bone turnover. There is a great need to anabolic agents for
reverse of osteoporosis. In this review, we summarize current informations about the ana‐
bolic agents.
© 2013 Okman-Kilic and Sagiroglu; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Parathormon
Parathyroid hormon (PTH) is released from the parathyroid glands and is an important reg‐
ulator in the bloodstream’s levels of calcium phosphorus. It stimulates both bone formation
and resorption [2,3]. Its intermittent low-dose using increases bone formation more than
bone resorption, leading to increased bone mass. Intermittent PTH administration increases
the number and activity of osteoblasts, enhances the mean wall thickness and trabecular
bone volume, and improves bone microarchitecture by establishing trabecular connectivity
and increasing cortical thickness [2,4].
Continuous infusions, which result in a persistent elevation of the serum parathyroid hor‐
mone concentration, lead to greater bone resorption than do daily injections, which cause
only transient increases in the serum parathyroid hormone concentration [5,6]. The anabolic
effects of PTH on bone formation are through the medium of PTH receptor-dependent
mechanisms. Teriparatide (PTH 1-34 ) is the biological active, a recombinant form of PTH [7].
Patients with fractures of postmenopausal osteoporosis administered teriparatide 20 and 40
μg/d in FPT (Fracture Prevention Trial) [8]. After 18 months teriparatide 20 μg/d reduces the
risk of spine fracture by %65 and non-spine fracture risk by %53. Over a median of 18
months spine fracture risk reduced by %69 and non-spine fracture risk reduced by %54 with
the 40 μg/d regimen [8].
Subbiah et al. reported the second patient to develop osteosarcoma [9]. Although teripara‐
tide reduces osteoporosis related fractures in select patient populations, important contrain‐
dications, such as prior radiation exposure, Paget’s disease of bone, unexplained elevations
of serum alkaline phosphate, open epiphysis should be considered before use.
It has been suggested teriparatide could be useful for treatment of severe and resistant
forms of osteoporosis to other medications [10].
In summary, we think that the clinical benefits of parathyroid hormone reflect its ability to
stimulate bone formation and thereby increase bone mass and strength. This hormone ap‐
pears to be effective in preventing fractures in postmenopausal women. Hovewer, it should
be used attention because of its important contraindications.
3. Stontium ranelate
Strontium ranelate is composed of an organic molecule (ranelic acid) and of two atoms of
stable non-radioactive strontium [11]. Strontium naturally present in trace amounts in hu‐
man body and has close similarities with calcium; act as calcium agonist in most of physio‐
logic process [12].
Strontium is similar to calcium in its absorption in the gastrointestinal track takes place in
two ways: passive diffusion and carrier mediated absorption. Both calcium and strontium
share the same carrier system, which tents to be greater affinity to calcium. High dietary in‐
take of calcium has been shown to reduce concurrent absorption of strontium [11].
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Ingested strontium is distributed in the body in three compartments: plasma extracellular
fluid; soft tissue and superficial zone of bone tissue; and bone itself, the greatest portion
is  the  calcified  tissues  [13].  In  bones,  total  amount  of  strontium  relatively  lower  than
amount  of  calcium.  After  its  absorption,  both  strontium  and  calcium  exhibit  the  same
characteristics [12].
The strontium levels in bone vary according to the anatomical  site.  However,  strontium
levels at different skeletal sites are strongly correlated [14]. The strontium levels in bone
also vary according to the bone structure and higher amounts of strontium are found in
cancellous bone than in cortical bone. Strontium is mainly incorporated by exchange on‐
to the crystal surface. In new bone, only a few strontium atoms may be incorporated in‐
to the crystal  by ionic substitution of  calcium [12,  14].  Bone strontium content is  highly
correlated  with  plasma  strontium  levels.  Mechanism  of  action  of  strontium  ranelate  is
shown in figure 1.
Figure 1. Mechanism of action of strontium ranelate in bone [13]
Strontium ranelate decreases osteoclast differentiation and activity [15]. Also able to increase
pre-osteoblast replication, collagen type I synthesis [16]. Therefore strontium ranelate has a
dual affect on bone remodeling, being able to stimulate bone formation by osteoblasts, a
property shared with bone-forming agents, and to inhibit bone resorption by osteoclasts, as
do anti-resorptive agents [17,18].
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Strontiun ranelate shows affect by binding calcium receptor in bone. Strontium has lower
affinity for calcium sensing receptor than calcium[19].
There are higher calcium ion concentrations within the bone microenvironment in case of
osteoclastic resorption. Affect of calcium receptor increases in higher extracellular calcium
concentrations. Strontium ranelate intake prevents bone loss with non-osteoporotic patients
in early post-menopausal period [19].
In the PREVOS study (PREVention Of early postmenopausal bone loss by Strontium rane‐
late) usage of strontium ranelate 1g/d for period of 2 years resulted in significantly high‐
er increase of femur BMD (bone mineral density). There was a significant increase in the
bone formation markers and concurrent increase of bone resorption markers has not been
recorded [20].
In  the  Treatment  of  Peripheral  Osteoporosis  (TROPOS)  study  strontium  ranelate  in‐
creased bone mineral density throughout the study, reaching at 3-yr 8.2% (femoral neck)
and 9.8% (total  hip).  Same study shows %36 decrease in hip fracture risk even in high-
risk subgroup over 3-yr period [21].
The Spinal Osteoporosis Therapeutic Intervention (SOTI) study investigated the safety of
strontium ranelate and its efficacy against vertebral fractures. In patients used strontium ra‐
nelate 2 g/d the risk of vertebral fractures was decreased by 41% over 3-yr [22].
In both studies strontium ranelate was well tolerated. The most common adverse events
consisted of nausea and diarrhea was disappeared after third month of treatment [21,22].
Therefore, we suggest that strontium ranelate has been proving antifracture efficacy in pa‐
tients with osteopenia and/or clinical risk factors and very old elderly. Also, it may contrib‐
ute to earlier and more effective intervention against fractures because of well- tolerated.
4. Prostaglandins
Prostaglandins  act  as  locally  acting  hormones,  developed as  new therapeutic  approach.
They  show  the  effect  and  are  metabolized  in  the  tissue  where  they  are  synthesized.
Prostaglandins are synthesized from arachidonic acid,  a  polyunsaturated fatty acid with
20-carbon chain [23].
Prostaglandins are produced from bone cells by mediated cyclooxygenase. Prostaglandin
production is regulated by mechanical stress, cytokines, growth factor and systemic hor‐
mones. Furthermore, prostaglandins are able to regulate their own production [24]. Prosta‐
glandins have both inhibitory and stimulatory effects on bone structuring. The most
prominent effect of prostaglandin E2 (PGE2) is to stimulate bone resorption and formation
[24]. PGE2 exerts its action through the cell surface receptors. Four subtypes of prostaglan‐
din E receptors (EP1, EP2, EP3 and EP4) [25,26] have been identified. PGE2 stimulates bone
formation by EP4 receptor mediation [26]. The importance and impact of prostaglandins in
bone metabolism is summarized in figure 2
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Figure 2. The mechanism of action and place of prostaglandins in bone metabolism [24]
It has been reported in certain studies that prostaglandins have anabolic effect on the bone
formation, therefore can be used in osteoporosis treatment [27].
It  has  been  demonstrated  that  systemic  PGE2  administration  stimulates  proliferation  of
osteoblast precursors or differentiation of osteoprogenitor cells in bone marrow and 4.7%
increase  in  bone  mass  eventually  was  found  in  the  same  study  [27].  Increase  of  total
bone  surface  by  means  of  osteoblast  stimulation  with  PGE2  administration  to  rats  has
been reported [28].
Misoprostol is a methylene analogue of prostaglandin E1 (PGE1) has been administered to
oophorectomized rats. Misoprostol is being used for treatment of gastric ulcer due to its cy‐
toprotective effect by inhibiting gastric acid and pepcin secretion [23]. Rats receiving miso‐
prostol had significantly reduced oophorectomy related bone loss at site of lumber spine.
Thus, it has been proposed that misoprostol is choice for treatment of post-menopausal os‐
teoporosis prophylaxis [29,30].
Misoprostol 800 μg/d had been administered for 6 moths to post-menopausal osteoporotic
patients. At the end of the treatment increase by 8.1% in femur bone mineral density, by 5%
increase in lumber spine bone mineral density and by 3.6% increase in Ward’s triangle bone
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mineral density have been found. It has been reported that misoprostol can be an alternative
on treatment of osteoporosis [31].
We think that misoprostol may be an alternative therapy for patients with osteopenia and
osteoporosis who are not suitable for hormone replacement therapy.
5. Sesamin
Sesamin is  a major lignan compound in sesame seeds.  Its  activity on bone cell  function
is  unclear.  Recently,  it  has  been  reported  that  sesamin  has  direct  effects  on  osteoblasts
by stimulating the expression of  essential  genes and key enzymes of  the bone minerali‐
zation process [32,33].
Wanachewin et al suggested that sesamin had the ability to trigger osteoblast differantiation
by activation of the p38 and ERK/MAPK (mitogen-activated protein kinase) signaling path‐
way and possibility indirectly regulate osteoclast development via the expression of OPG
and RANKL in osteoblasts [32].
The MAPK/ERK pathway is a chain of proteins in the cell that transmits a signal from a re‐
ceptor on the surface of the cell to the DNA in the nucleus of the cell. MAPKs play impor‐
tant roles in cellular response to growth factors, cytokines, or environmental stress.
They are  classified into  four  classes:  extracellular  signal-regulated kinases  (ERKs),  c-Jun
N-terminal  kinase  or  stress-activated protein  kinase,  p38  MAPKs,  and ERK5 [34].  ERKs
are  involved in  cell  proliferation/transformation and survival.  p38  MAPKs are  involved
in  many  cellular  processes,  such  as  inflammatory  responses,  osteoblast  differentiation,
apoptosis [35,36].
We think that sesamin which is a phytochemical agent, may be effective addition to osteo‐
porotic therapy. Future studies are needed.
6. Statins
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase.
Usually,  it  has  been  known  that  they  have  efficacy  and  credibility  on  coronary  artery
diseases  and  hyperlipidemia  [37,38].  First,  Mundy et  al  showed that  statins  lead  to  in‐
crease  90  %  in  the  trabecular  bone  volume  by  stimulating  bone  formation  invitro  and
therefore it was started to studies investigating the place of statins for osteoporosis treat‐
ment [39]. Hamelin et al suggested that statins decrease the bone destruction by supress‐
ing the formation of  the mevalonate  that  it  is  an important  precursor  on the control  of
osteoclastic activity as bisphosphonates [40].
It was reported that statins have efficacy on the bone metabolism, by increasing bone mor‐
phogenetic protein 2 (BMP2) activation stimulated osteoblastic cell proliferation and matu‐
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ration [41]. Maeda et al showed that hydrophobic statins such as simvastatin, atorvastatin,
and cerivastatin stimulated VEGF expression by osteoblasts via reduced protein prenylation
and the phosphatidylinositide-3 kinase pathway, promoting osteoblastic differentiation [42].
In 2009 Pault et al revealed a dose-dependent effect and improved fracture healing under
local application of simvastatin [43].
Fukui et al reported that the effect of the systemic administration of statins was limited due
to its metabolism in the liver and high-dose administration may cause adverse side effects.
They locally applied with gelatin hydrogel to fracture sites at a dose similar to that used in
clinical settings and shown to induced fracture union in a rat unhealing bone fracture model
via its effect on both angiogenesis and osteogenesis [44].
We suggest that the results of studies also point to the need for more information in order to
particularly gelatin hydrogel form.
7. Growth hormone and IGF-I
It is known that growth hormone (GH) is important in the regulation of longitudinal bone
growth [45]. Several in vivo and in vitro studies have demonstrated that GH is important in
the regulation of both bone formation and bone resorption. In Figure 3 a model for the cellu‐
lar effects of GH in the regulation of bone remodeling is showed [45].
Figure 3. The mechanism of action at the cellular level for GH in regulation of bone remodeling. The left part of the
figure represents osteoclast-mediated bone resorption. The right part represents osteoblast-mediated bone forma‐
tion. ? indicates that both stimulatory and inhibitory effects have been shown [45]
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GH increases bone formation in two ways [46]:
1. via a direct interaction with GHRs on osteoblasts
2. via an induction of endocrine and autocrine/paracrine IGF-I (Insulin like Growth Fac‐
tor-1).
rhGH (recombinant human Growth Hormone) increases bone turnover in normal subjects
and improves bone mineral metabolism in postmenopausal females [45]. GH treatment also
results in increased bone resorption. It is still unknown whether osteoclasts express func‐
tional GHRs, but recent in vitro studies indicate that GH regulates osteoclast formation in
bone marrow cultures [45, 46]. Possible modulations of the GH/IGF (Insulin like Growth
Factor) axis by glucocorticoids and estrogens are also included in Fig. 3 [45].
Bone is the second richest source of IGF-I in the body. Locally this peptide promotes osteo‐
blast differentiation and growth [48]. Recently, studies show that low levels of IGF-I are as‐
sociated with a greater risk of hip and spine fractures [49–51]. Hence, there is a strong
opinion for considering human GH or IGF-I as potential anabolic agents for the treatment of
osteoporosis. There are potential advantages for using rhIGF-I (recombinant human Insulin
like Growth Factor-1) compared with rhGH in the treatment of osteoporosis. These include
1. more direct stimulation of bone formation,
2. bypass of skeletal GH resistance that can be present, and
3. a reduction in GH-induced side-effects such as carpal tunnel and diabetes mellitus. [47]
It was reported that low doses of rhIGF-I may directly increase osteoblastic function with
only a minimal increase in bone resorption [52]. In 2008, it was suggested a potential role for
IGF-1 in the early identification of women at risk for low bone mass and osteoporosis. They
suggested measuring the serum level of IGF-1 in women around 40 years old. When its val‐
ue is 1.5 SD below the peak, BMD measurement by DXA could be considered [53]
There are limited number studies using rhIGF-I than rhGH. Therefore, these advantages
have not been validated yet.
8. Sodium fluoride
Sodium fluoride is the first anabolic agentsto be used in the treatment of postmenopausal
osteoporosis. Side-effects, consisting of upper gastrointestinal symptoms and a lower ex‐
tremity pain syndrome, are common.
Using slow release formulation of sodium fluoride, it was showed a 50% reduction in verte‐
bral fracture incidence with impressive increases in bone mass [54-56]. More recently, it has
been suggested that a different formulation of fluoride, monofluorophosphate when is used
in lower dosages and more favorable formulations, gastrointestinal side-effects are reduced
[57-59]. However, consensus about its clinical utility has still not been reached.
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9. Other potential agents for anabolic treatment of osteoporosis
Bortezomib: There are multiple potential alternative agents for increasing bone formation.
A potential treatment is to target the osteoblast proteasome. It was reported that the protea‐
some inhibitor bortezomib (Bzb) had bone forming effects in patients with multiple mye‐
lome [60]. The mechanism for Bzb’s effects on osteoblastic differentiation has not been
clearly defined.
It  was showed that Bzb with lenalidomide or thalidomide may increase bone formation
by stimulating osteoblast activity and inhibiting osteoclastic bone destruction, respective‐
ly Figure 4.
Figure 4. Bzb’s action on bone formation in the patients with multiple myeloma [60]
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Oxytocin: An other approach is oxytocin (OT) that increases osteoblastic bone formation. It
has been reported that OT may regulate maternal skeletal homeostasis during pregnancy
and lactation. The fetal skeleton is unlikely to be mineralized effectively in the absence of
calcium mobilized from the maternal skeleton [61]. It has been suggested that elevated OT
levels during pregnancy and lactation not only enhance bone resorption by increasing the
number of osteoclasts to make maternal calcium existing to the fetus, but also prevent unre‐
stricted bone removal by inhibiting the activity of mature osteoclasts. Therefore, it was re‐
ported that recombinant OT or its analogs because of its skeletal anabolic action, might have
potential utility in therapy for human osteoporosis [61].
Beta-blocker: Wiens et al found that beta-blocker use was associated with a significant de‐
crease in fracture risk [62]. However, in 2008, Reid determinated that there was no any evi‐
dence to support the hypothesis that beta‚-blockers reduce fracture numbers [63]. In 2012,
Yang et al reported that beta-blockers are associated with reduced risk of fracture in older
adults, but the effect size is likely to be modes [64]t. In summary, there was no an adequate
evidence to support using beta-blockers in the treatment of osteoporosis.
Lithium: The mean (+/-SD) bone density in lithium treated patients was reported that 4.5%
higher at the spine (P<0.05), 5.3% higher at the femoral neck (P<0.05) and 7.5% higher at the
trochanter (P<0.05). In addition, lithium treated patients had lower serum total ALP
(P<0.005), lower serum osteocalcin (P<0.005) and lower serum CTX (P<0.05) but the totalcal‐
cium, PTH and urinary calcium excretion did not differ significantly between patients and
controls. In conclusion, it was suggested that therapy with lithium carbonate may preserve
or enhance bone mass [65].
Figure 5. Modulation of Wnt signaling by sclerostin [73]
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Anti-sclerostin monoclonal antibody: Sclerostin is a protein encoded by the SOST gene in
osteocytes. It inhibits osteoblastic bone formation [66,67]. The binding of Wnt proteins to the
LRP5/6-Frizzled co-receptor on the cell membrane of osteoblasts leads to stabilization of in‐
tracellular beta-catenin and regulation of gene transcription that promotes osteoblastic bone
formation. Sclerostin is a modulator of osteoblast function. It antagonizes Wnt signaling and
inhibits osteoblastic bone formation [68]. Recent studies reported that anti-sclerostin therapy
enhances fracture healing and bone repair.[69-71]. AMG 785 is a humanized sclerostin mon‐
oclonal antibody, was first studied in humans. It enhances Wnt signaling and increase osteo‐
blastic bone formation [72]. Figure 5
Treatment with AMG 785 has been well tolerated. In postmenopausal women with low
bone mineral density (BMD) after 12 months of AMG 785 administration, increase in BMD is
determined. Although there is no evidence that AMG 785 increases the risk of osteosarcoma,
new studies are needed to modify this risk.
10. Conclusion
Aging is associated with impaired bone formation which is a principal pathogenetic cause
mediating bone fragility in osteoporosis. Ideally, patients at high risk of fracture should be
identified early and treated by a combination of lifestyle changes, correction of secondary
causes of osteoporosis, and specific treatments to improve bone density and decrease frac‐
ture risk. By now, there were a limited number of therapeutic agent for activating bone for‐
mation and increasing bone mass and strength. More effective and better tolerated therapies
will become available soon. We think that new treatments will be able to contribute to in‐
crease the currently low treatment rate of even severe osteoporosis by allowing approaches
aimed at minimising fracture risk at the individual patient level.
Author details
Tulay Okman-Kilic1 and Cengiz Sagiroglu2
*Address all correspondence to: ajlankilic@hotmail.com
1 Department of Obsterics and Gynecology, Trakya University, Medical Faculty, Edirne,
Turkey
2 Tasyapi Health Group, Istanbul, Turkey




[1] World Health Organisation. Assessment of fracture risk and its application to screen‐
ing for postmenopausal osteoporosis. World Health Organisation Technical Report
Series. Geneva: WHO, 1994.
[2] Hock JM, Gera I. Effects of Continuous and Intermittent Administration and Inhibi‐
tion of Resorption on The Anabolic Response of Bone to Parathyroid Hormone. J
Bone Miner Res 1992;7:65–72.
[3] Schlüter KD. PTH and PTHrP: Similar Structures but Different Functions. News
Physiol Sci. 1999;14:243-49.
[4] Marie PJ, Kassem M. Osteoblasts in Osteoporosis: Past, Emerging, and Future Ana‐
bolic Targets. Eur J Endocrinol. 2011;165 (1):1-10.
[5] Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid Hormone Stimulates The
Bone Apposition Rate Independently of Its Resorptive Action: Differential Effects of
Intermittent and Continuous Administration. Endocrinology 1982;110:506-12.
[6] Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of The Effects of Intermittent and
Continuous Administration of Human Parathyroid Hormone (1-34) on Rat Bone.
Bone 1995;16:477-484.
[7] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of
Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmeno‐
pausal Women with Osteoporosis. N Engl J Med 2001;344:1434-1441.
[8] Geusens P, Reid D. Newer drug treatments: their effects on fracture prevention. Best
Practice and Clinical Rheumatology 2005;19(6):983-9.
[9] Subbiah V, Madsen VS, Raymond AK, Benjamin RS & Ludwig JA. Of Mice and Men:
Divergent Risks of Teriparatide-Induced Osteosarcoma. Osteoporosis International
2010;21: 1041–1045.
[10] Manuele S, Sorbello N, Puglisi N, Grasso S, La Malfa L, Durbino G, et al. The teri‐
paratide in the treatment of severe senile osteoporosis. Arch Gerontol Geriatr
2007;1:249-58.
[11] Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treat‐
ment of osteoporosis. Drugs of Today 2003;39(2):89-101.
[12] Nielsen SP. The biological role of strontium. Bone 2004;35:583-8.
[13] Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic poten‐
tial of strontium in bone. Carcified Tissue International 2001;69:121-9.
[14] Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P, et al. Incorporation and
distribution of strontium in bone. Bone 2001;28:446-53.
Topics in Osteoporosis252
[15] Baron R, Tsouderos Y. İn vitro effects of S12911-2 on osteoclast function and bone
marrow macrophege differentiation. European Journal of Pharmocology
2002;450:11-7.
[16] Reginster JY, Lecart MP, Deroisy R, Lousberg C. Strontium ranelate: a new paradigm
in the treatment of osteoporosis. Expert Opin Investig Drugs 2004;13(7):857-64.
[17] Marie PJ. Strontium ranelate: a physiological approach for optimizing bone forma‐
tion and resorption. Bone 2006;38:10-4.
[18] Ammann P, Shen V, Robin B, Mauras Y, Bonjour J-P, Rizzoli R. Strontium ranelate
improves bone resistnce by increasing bone mass and improving architecture in in‐
tact female rats. Journal of Bone and Mineral Research 2004;19(12):2012-20.
[19] Coulombe J, Faure H, Robin B, Ruat M. In vitro effects of strontium ranelate on the
extracellular calcium-sensing receptor. BBRC 2004;323:1184-90.
[20] Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention or early
postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-
masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int
2002;13:925-31.
[21] Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al.
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal
women with osteoporosis: treatment of peripheral osteoporosis (tropos) study. The
Journal of Clinical Endocrinology and metabolism 2005;90(5):2816-22.
[22] Meunier JM, Roox C, Seeman E, Ortolani S, Budurski J, Spencor T, et al. The effects of
strontium ranelate on the risk of vertebral fracture in women with postmenopausal
osteoporosis. The New England Journal of Medicine 2004;350:459-68.
[23] Mycek MJ, Harvey R, Champe P (Çeviri: Ş. Oktay). Farmakoloji. İstanbul: Nobel Tıp
Kitabevleri Ltd. Şti.; 1998:419-20.
[24] Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The Jour‐
nal of Clinical Investigation 2005;115(12):3318-25.
[25] Watkins BA, Li Y, Seifert MF. Lipids as modulators of bone remodelling. Current
Opinion in Clinical Nutrition and Metabolic Care 2001;4:105-10.
[26] Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, et al. Stimu‐
lation of bone formation and prevention of bone loss by prostaglandin EP4 receptor
activation. PNAS 2002;99(7):4580-5.
[27] Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of
PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone
1997;20(6):521-6.
[28] Yao W, Jee SSW, Zhou H, Lu J, Cui L, Setterberg R, et al. Anabolic effect of prosta‐
glandin E2 on cortical bone of aged male rats comes mainly from modeling depend‐
ent bone gain. Bone 1999;25(6):697-702.
Anabolic Agents as New Treatment Strategy in Osteoporosis
http://dx.doi.org/10.5772/54452
253
[29] Sonmez AS, Birincioglu M, Özer MK, Kutlu R, Chuong CJ. Effects of misoprostol on
bone loss in ovariectomized rats. Prostaglandins and other Lipid Mediators
1999;57:113-8.
[30] Ahmet-Camcioglu N, Okman-Kilic T, Durmus-Altun G, Ekuklu G, Kucuk M. Effects
of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariec‐
tomized rats. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):192-4.
[31] Yasar L, Sönmez AS, Utku N, Özcan J, Çebi Z, Savan K, et al. Effect of misoprostol on
bone mineral density in women with postmenopausal oateoporosis. Prostaglandins
and Other Lipid Mediators 2006;79:199-205.
[32] Wanachewin O, Boonmaleerat K, Pothacharoen P, Reutrakul V, Kongtawelert P. Ses‐
amin Stimulates Osteoblast Differentiation Through p38 and ERK1/2 MAPK Signal‐
ing Pathways. BMC Complement Altern Med 2012;12(1):71
[33] Boulbaroud S, Mesfioui A, Arfaoui A, Ouichou A, El-Hessni A. Preventive effects of
flaxseed and sesame oil on bone loss in ovariectomized rats. Pak J Biol Sci
2008;11(13):1696–1701.
[34] Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37–
40.
[35] Suzanne M, Irie K, Glise B, Agnes F, Mori E, Matsumoto K, Noselli S. The Drosophila
p38 MAPK pathway is required during oogenesis for egg asymmetric development.
Genes Dev 1999;13:1464–1474.
[36] Hu Y, Chan E, Wang SX, Li B. Activation of p38 mitogen-activated protein kinase is
required for osteoblast differentiation. Endocrinology. 2003;144(5):2068-74.
[37] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-
analysis of randomized controlled trials. JAMA 1999; 282 (24): 2340-6.
[38] Prevention of cardiovascular events and death with pravastatin in patients with cor‐
onary heart disease and a broad range of initial cholesterol levels. The Long-Term In‐
tervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med
1998; 339 (19): 1349-57.
[39] Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in ro‐
dents by statins. Science 1999; 286 (5446): 1946-9.
[40] Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: revelance for the pharmacology
and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19:
26-37.
[41] Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
Osteoporos Int 2003; 14 (4): 273-82.
[42] Maeda T, Kawane T, Horiuchi N. Statins Augment Vascular Endothelial Growth Fac‐
tor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation. Endocrinol‐
ogy 2003;144(2):681–692 doi: 10.1210/en.2002-220682.
Topics in Osteoporosis254
[43] Pauly S, Luttosch F, Morawski M, Haas NP, Schmidmaier G, Wildemann B. Simvas‐
tatin locally applied from a biodegradable coating of osteosynthetic implants im‐
proves fracture healing comparable to BMP-2 application. Bone. 2009;45:505–511. doi:
10.1016/j.bone.2009.05.010.
[44] Fukui T, Ii M, Shoji T, Matsumoto T, Mifune Y, Kawakami Y, Akimaru H, Kawamoto
A, Kuroda T, Saito T, Tabata Y, Kuroda R, Kurosaka M, Asahara T. Therapeutic effect
of local administration of low-dose simvastatin-conjugated gelatin hydrogel for frac‐
ture healing. J Bone Miner Res. 2012 May;27(5):1118-31. doi: 10.1002/jbmr.1558.
[45] Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT, Slootweg M. Growth Hor‐
mone and Bone. Endocrine Reviews 1998; 19: (1) 55-79.
[46] Ransjö M, Lerner U, Ohlsson C. Growth hormone inhibits formation of osteoclast-
like cells in mouse bone marrow cultures. J Bone Miner Res 1996;11 [Suppl]:T394
[47] Rosen CJ, Bilezikian JP. Clinical Review 123: Hot Topic Anabolic Therapy for Osteo‐
porosis J Clin Endocrinol Metab 2001;86: 957–964.
[48] Donahue LR, Rosen CJ. IGFs and bone. The osteoporosis connection revisited. Proc
Soc Exp Biol Med. 1998;219:1–7.
[49] Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of IGF-I, IGFBP-2,
and IGFBP-3 in osteoporotic patients with and without spine fractures. J Bone Miner
Res. 1997;12:1272–1279.
[50] Bauer DC, Rosen C, Cauley J, Cummings SR. Low serum IGF-I but not IGFBP-3 pre‐
dicts hip and spine fracture: the study of osteoporotic fracture.J Bone Miner Res.
1998;23:S561.
[51] Rosen CJ, Pollak MF. IGF-I and aging: a new perspective for a new century. Trends
Endocrinol Metab. 1999;10:136 –142.
[52] Ghiron L, Thompson J, Halloway L, Butterfield GE, Hoffman A, Marcus R. Effects of
rhGH and IGF-I on bone turnover in elderly women. J Bone Miner Res.1995;10:1844 –
1852.
[53] Liu JM, Zhao HY, Ning G, Chen Y, Zhang LZ, Sun LH, Zhao YJ, Xu MY, Chen JL
IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and
postmenopausal women. J Bone Miner Metab (2008) 26:159–164
[54] Pak CYC, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective
treatment of osteoporosis with intermittent slow release NaF: augmentation of verte‐
bral bone mass and inhibition of fractures. J Clin Endocrinol Metab.1989; 68:150 –159.
[55] Pak CYC, SakhaeeK, Adams Huet B, Piziak V, Petersen RD, Poindexter JR. Treatment
of postmenopausal osteoporosis with slow-release NaF. Ann Intern Med.
1995;123:401– 408.
[56] Pak CYC, Zerwekh JE, Antich PP, Bell NH, Singer FR. Slow-release sodium fluoride
in osteoporosis. J Bone Miner Res. 1996;5:561–564.
Anabolic Agents as New Treatment Strategy in Osteoporosis
http://dx.doi.org/10.5772/54452
255
[57] Ringe JD, Kipshoven C, Coster A, Umbach R. Therapy of established postmenopaus‐
al osteoporosis with monofluorophosphate plus calcium: dose related effects on bone
density and fracture rate. Osteop Int.1999; 9:171–178.
[58] Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monfluorophosphate
plus calcium on vertebral fracture rate in postmenopausal women with moderate os‐
teoporosis.Arandomized controlled trial. Ann Intern Med. 1998;129:1– 8.
[59] Ringe JD, dorst A, Kipshoven C, Rovati LC, Setnikar I. Avoidance of vertebral frac‐
tures in men with idiopathic osteoporosis by a three-year therapy with calcium and
low-dose intermittent monofluorophosphate. Osteop Int. 1998;8:47–52.
[60] Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida SI, Okano A, Okamoto M and
InabaT. High serum bone-specific alkaline phosphatase level after bortezomib-com‐
bined therapy in refractory multiple myeloma: possible role of bortezomib on osteo‐
blast differentiation. Leukemia 2005;19, 1102–1103.
[61] Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, Patano N,
Strippoli M, Vergari R, Mancini L, Colucci S, Grano M, Faccio R, Liu X, Li J, Usmani
S, Bachar M, Bab I, Nishimori K, Young LJ, Buettner C, Iqbal J, Sun L, Zaidi M, Zal‐
lone A. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A.
2009;106(17):7149-54
[62] Wiens M, Etminan M, Gill SS, Takkouche B. Effects of anti-hypertensive drug treat‐
ments on fracture outcomes: a meta-analysis of observational studies. J Intern Med
2006;260:350-62
[63] Reid IR. Effects of beta-blockers on fracture risk. J Musculoskelet Neuronal Interact.
2008 Apr-Jun;8(2):105-10. Review.
[64] Yang S, Nguyen ND, Eisman JA, Nguyen TV. Association between beta-blockers and
fracture risk: A Bayesian meta-analysis. Bone. 2012;51(5):969-974.
[65] Zamani A, Omrani GR, Nasah MM. Lithium's effect on bone mineral density. Bone.
2009 Feb;44(2):331-4
[66] Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW,
Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone for‐
mation. FASEB J 2005;19(13):1842-1844.
[67] van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M,
Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-ex‐
pressed negative regulator of bone formation, but not a classical BMP antagonist. J
Exp Med 2004;199(6):805-814.
[68] Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteopo‐
rosis. Discov Med. 2011;12(65):263-73. Review.
[69] Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y,
Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony
Topics in Osteoporosis256
S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, et al. Targeted deletion of the sclero‐
stin gene in mice results in increased bone formation and bone strength. J Bone Min‐
er Res 2008; 23(6):860-869.
[70] Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V,
Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Koste‐
nuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases
bone formation, bone mass, and bone strength in a rat model of postmenopausal os‐
teoporosis. J Bone Miner Res 2009b;24(4):578-588.
[71] Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y,
Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD,Lightwood DJ,
Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty
C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone forma‐
tion, bone mineral density, and bone strength. J Bone Miner Res.2010;25(5):948-59.
[72] Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled,
randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res
2011;26(1):19-26.
[73] Lawrence G. Raisz. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J
Clin Invest .2005;115(12):3318-25.
[74] Amgen and UCB. Amgen and UCB announce positive phase 2 results of AMG 785/
CDP7851 in patients with postmenopausal osteoporosis (PMO). http://
www.amgen.com/media_pr_detail.jsp?releaseID=1553039. (accessed 1 Jun 2011).
Anabolic Agents as New Treatment Strategy in Osteoporosis
http://dx.doi.org/10.5772/54452
257

